These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37806829)

  • 1. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
    Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
    HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases.
    Chen Q; Li K; Rhodin KE; Masoud SJ; Lidsky ME; Cai J; Wei Q; Luo S; Zhao H
    J Surg Oncol; 2023 May; 127(6):945-955. PubMed ID: 36807890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.
    Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A
    J Neuroendocrinol; 2024 Aug; 36(8):e13399. PubMed ID: 38760997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
    Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
    J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.
    Lewis A; Raoof M; Ituarte PHG; Williams J; Melstrom L; Li D; Lee B; Singh G
    Ann Surg; 2019 Dec; 270(6):1131-1137. PubMed ID: 29746336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.
    Liu Y; Wang Z; Lin Q; Cui R; Tang W; Li G; Wang Z
    BMC Gastroenterol; 2023 Nov; 23(1):408. PubMed ID: 37993767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.
    Li Z; Ren H; Wang T; Zhang X; Zhao L; Sun C; Niu P; Guo C; Chen Y; Zhao D
    Front Oncol; 2022; 12():930491. PubMed ID: 35912176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary tumor resection and lymph node dissection improve survival in
    Wu C; Zhang X; Wang T; Zhou H; Guo C; Chen Y; Zhao D
    Transl Cancer Res; 2020 May; 9(5):3312-3323. PubMed ID: 35117698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Metastasectomy in Patients with Liver-Only Metastases from Gastric Adenocarcinoma.
    Ziogas IA; Thielen ON; Ghaffar SA; Yee EJ; Khomiak A; Durden JA; Kim S; Schulick RD; Gleisner AL; McCarter MD; Mungo B
    Ann Surg Oncol; 2024 Sep; ():. PubMed ID: 39349911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases.
    Mou Y; Wang ZY; Tan CL; Chen YH; Liu XB; Ke NW
    Front Oncol; 2022; 12():838103. PubMed ID: 35350567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.
    de Mestier L; Neuzillet C; Pozet A; Desot E; Deguelte-Lardière S; Volet J; Karoui M; Kianmanesh R; Bonnetain F; Bouché O
    Eur J Surg Oncol; 2014 Jun; 40(6):685-91. PubMed ID: 24630774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
    Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
    J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.